Publications by authors named "John Hackmann"

Claim this Profile
I
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial.
Darren Korbie, Clare Stirzaker, Oleg Gluz, Christine Zu Eulenburg, Ulrike Nitz, John Hackmann

Mol Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.
André Pfob, Lie Cai, Andreas Schneeweiss, Geraldine Rauch, Bettina Thomas, John Hackmann

Ann Surg Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic and sensitive method for critical reagent antibody evaluation with PCA technology.
Jian Gong, Xing Wang, John Hackmann

Bioanalysis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Oleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, John Hackmann

Clin Cancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, Matthias Christgen, Ronald Kates, John Hackmann

Breast Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
André Pfob, Chris Sidey-Gibbons, Geraldine Rauch, Bettina Thomas, Benedikt Schaefgen, John Hackmann

J Clin Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03.
Joerg Heil, André Pfob, Hans-Peter Sinn, Geraldine Rauch, Paul Bach, John Hackmann

Ann Surg· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Sonia L Villegas, Valentina Nekljudova, Nicole Pfarr, Jutta Engel, Michael Untch, John Hackmann

Eur J Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
Monika Graeser, Friedrich Feuerhake, Oleg Gluz, Valery Volk, Michael Hauptmann, John Hackmann

J Immunother Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Oleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, Matthias Christgen, Daniel Gebauer, John Hackmann

Int J Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
Michael Untch, Christian Jackisch, Andreas Schneeweiss, Sabine Schmatloch, Bahriye Aktas, John Hackmann

J Clin Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
Joerg Heil, Peter Sinn, Hannah Richter, André Pfob, Benedikt Schaefgen, John Hackmann

BMC Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, Matthias Christgen, Eva-Maria Grischke, John Hackmann

J Natl Cancer Inst· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of nab-paclitaxel 125 mg/m and nab-paclitaxel 150 mg/m compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).
Jenny Furlanetto, Christian Jackisch, Michael Untch, Andreas Schneeweiss, Sabine Schmatloch, John Hackmann

Breast Cancer Res Treat· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Michael Untch, Christian Jackisch, Andreas Schneeweiss, Bettina Conrad, Bahriye Aktas, John Hackmann

Lancet Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Gunter von Minckwitz, Bettina Conrad, Toralf Reimer, Thomas Decker, Holger Eidtmann, John Hackmann

Cancer· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis